TIDMRENE

RNS Number : 8537R

ReNeuron Group plc

14 December 2016

 
 14 December 2016   AIM: RENE

ReNeuron Group plc

("ReNeuron" or the "Company")

Director Share Purchase

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 14 December 2016 that, on the same day, Olav Hellebø, the Company's Chief Executive Officer, acquired 346,644 ordinary shares of 1p each ("Ordinary Shares") at a price of 2.8848p per share.

Following this share purchase, Olav Hellebø's total beneficial interest in the Company is 669,422 Ordinary Shares, representing 0.021 per cent of the Company's total voting rights.

ENQUIRIES:

 
ReNeuron                                                            +44 (0)20 3819 8400 
Olav Hellebø, Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
Buchanan                                                            +44 (0) 20 7466 5000 
Mark Court, Sophie Cowles, Stephanie Watson 
 
Stifel Nicolaus Europe Limited                                      +44 (0) 20 7710 7600 
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker)

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

(Disclosure in relation to purchase of Ordinary Shares)

 
  1   Details of the person discharging managerial 
       responsibilities / person closely associated 
---  ------------------------------------------------------------ 
 a)   Name                      Olav Hellebø 
---  ------------------------  ---------------------------------- 
 2    Reason for the notification 
---  ------------------------------------------------------------ 
 a)   Position/status           Chief Executive Officer 
---  ------------------------  ---------------------------------- 
 b)   Initial notification      Initial notification 
       /Amendment 
---  ------------------------  ---------------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, 
       auctioneer or auction monitor 
---  ------------------------------------------------------------ 
 a)   Name                      ReNeuron Group plc 
---  ------------------------  ---------------------------------- 
 b)   LEI                       N/A 
---  ------------------------  ---------------------------------- 
 4    Details of the transaction(s): section 
       to be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) 
       each date; and (iv) each place where 
       transactions have been conducted 
---  ------------------------------------------------------------ 
 a)   Description of            Ordinary Shares 0.01p 
       the financial 
       instrument, type          RENE - GB00B0DZML60 
       of instrument 
       Identification 
       code 
---  ------------------------  ---------------------------------- 
 b)   Nature of the             Purchase of ordinary shares 
       transaction 
---  ------------------------  ---------------------------------- 
 c)   Price(s) and                Price(s)   Volume(s) 
       volume(s)                  ---------  ---------- 
                                   2.8848p    346,644 
                                  ---------  ---------- 
---  ------------------------  ---------------------------------- 
 d)   Aggregated information    N/A 
---  ------------------------  ---------------------------------- 
 e)   Date of the transaction   14 December 2016 
---  ------------------------  ---------------------------------- 
 f)   Place of the              London Stock Exchange, AIM Market 
       transaction 
---  ------------------------  ----------------------------------

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHUSRURNKAUAAA

(END) Dow Jones Newswires

December 14, 2016 07:15 ET (12:15 GMT)

Reneuron (LSE:RENE)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Reneuron Charts.
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Reneuron Charts.